Clinical Observation of Anshen Buxin Gao in Treating Coronary Heart Disease Complicated with Somatization Disorder After PCI
10.13422/j.cnki.syfjx.20250828
- VernacularTitle:安神补心膏治疗冠心病PCI术后合并躯体化障碍的临床观察
- Author:
Yaozhong ZHOU
1
;
Yanzhe WANG
1
;
Wan CAI
2
;
Wenjuan CAI
1
;
Yan SHAO
1
;
Yi SHEN
1
;
Yan WANG
1
;
Qiusheng SHEN
1
Author Information
1. Changshu Affiliated Hospital of Nanjing University of Chinese Medicine，Changshu 215500，China
2. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine， Shanghai 201203，China
- Publication Type:Journal Article
- Keywords:
Anshen Buxin Gao;
after percutaneous coronary intervention （PCI）;
somatization disorder;
anxiety-depression;
heart rate variability
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(13):197-204
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy of Anshen Buxin Gao in patients with coronary artery disease （CAD） complicated with somatization disorder after percutaneous coronary intervention （PCI）， as well as its effect on heart rate variability （HRV）. MethodsA total of 96 patients with somatization disorder after PCI were selected and randomized into control and treatment groups （48 cases）. On the basis of standardized Western medical treatment for CAD， the control group received Dailixin， while the treatment group received Dailixin combined with Anshen Buxin Gao. The somatic symptom scale （SSS）， generalized anxiety disorder 7-item scale （GAD-7）， patient health questionnaire-9 （PHQ-9）， and self-rating scale of sleep （SRSS） scores in both groups were recorded before and after treatment. The traditional Chinese medicine symptom efficacy， HRV， and incidence of adverse drug reactions were observed. ResultsA total of 90 patients completed the trial， encompassing 45 patients in the control group and 45 patients in the treatment group. Baseline characteristics between the two groups showed no statistically significant differences， indicating comparability. After treatment， both groups exhibited reductions in SSS， GAD-7， and PHQ-9 scores （P<0.05）， and the treatment group outperformed the control group in alleviating somatic symptoms and anxiety-depression symptoms （P<0.05）. The control group did not achieve a significant reduction in SRSS score， whereas the treatment group effectively lowered the SRSS score （P<0.05）. Regarding traditional Chinese medicine symptom efficacy， the total response rate in the treatment group was 91.1% （41/45）， which was higher than that （71.1%， 32/45） in the control group （Z=-2.663， P<0.05）. Both groups improved HRV in patients with somatization disorder， and the treatment group showed greater improvement （P<0.05）. There were no serious clinical adverse events during the study period. The incidence of adverse reactions in the treatment group was 6.7% （3/45）， which was lower than that （14/45， 31.10%） in the control group （χ2=7.252， P<0.05）. ConclusionThe addition of Anshen Buxin Gao to Dailixin therapy significantly alleviates the clinical symptoms and improves the sleep quality， treatment efficacy， and HRV in patients with CAD complicated with somatization disorder after PCI， while reducing the adverse effects associated with Dailixin alone. This approach demonstrates considerable clinical value and warrants further promotion.
